---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-001375"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-07-28T23:59:59+00:00"
generated_at: "2026-06-12T22:53:45.228346+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lexaria forms CPG subsidiary Lexaria Nutraceutical, amends pharma license; nicotine study results due within 2 weeks

## Summary
- New wholly-owned subsidiary Lexaria Nutraceutical Corp. receives exclusive perpetual license for DehydraTECH in consumer packaged goods (excluding cannabis/nicotine).
- Lexaria Pharmaceutical Corp. license amended to focus solely on pharmaceutical products (excluding nicotine).
- Human nicotine study NIC-H22-1 (36 smokers, crossover PK) completed dosing; results expected in ~2 weeks.
- Oral nicotine pouch market was $2.33B in 2020, CAGR 30.7%, projected to reach $21.84B by 2027.

## SEC filing metadata
- accession: 0001640334-23-001375
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423001375/0001640334-23-001375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423001375/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-001375
- JSON: https://secwatch.observer/filing/0001640334-23-001375.json
- Plain text: https://secwatch.observer/filing/0001640334-23-001375.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.